These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 12883196

  • 1. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis.
    Chueh SC, Kahan BD.
    Transplantation; 2003 Jul 27; 76(2):375-82. PubMed ID: 12883196
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients.
    Langer RM, Kahan BD.
    Transplantation; 2003 Jul 27; 76(2):318-23. PubMed ID: 12883185
    [Abstract] [Full Text] [Related]

  • 3. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus.
    Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G.
    Liver Transpl; 2001 May 27; 7(5):401-8. PubMed ID: 11349259
    [Abstract] [Full Text] [Related]

  • 4. A long-term study on hyperlipidemia in stable renal transplant recipients.
    Tse KC, Lam MF, Yip PS, Li FK, Lai KN, Chan TM.
    Clin Transplant; 2004 Jun 27; 18(3):274-80. PubMed ID: 15142048
    [Abstract] [Full Text] [Related]

  • 5. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy.
    Charco R, Cantarell C, Vargas V, Capdevila L, Lázaro JL, Hidalgo E, Murio E, Margarit C.
    Liver Transpl Surg; 1999 May 27; 5(3):204-8. PubMed ID: 10226111
    [Abstract] [Full Text] [Related]

  • 6. Median effect analysis of efficacy versus adverse effects of immunosuppressants.
    Kahan BD, Kramer WG.
    Clin Pharmacol Ther; 2001 Jul 27; 70(1):74-81. PubMed ID: 11452247
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, Salerno MP, Castagneto M.
    Transplant Proc; 2006 May 27; 38(4):1034-6. PubMed ID: 16757255
    [Abstract] [Full Text] [Related]

  • 9. Ischemic heart disease after renal transplantation in patients on cyclosporine in Spain.
    Marcén R, Morales JM, Arias M, Fernández-Juárez G, Fernández-Fresnedo G, Andrés A, Rodrigo E, Pascual J, Domínguez B, Ortuño J.
    J Am Soc Nephrol; 2006 Dec 27; 17(12 Suppl 3):S286-90. PubMed ID: 17130276
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 14. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
    Porrini E, Delgado P, Alvarez A, Cobo M, Pérez L, González-Posada JM, Hortal L, Gallego R, García JJ, Checa M, Morales A, Salido E, Hernández D, Torres A.
    Nephrol Dial Transplant; 2008 Apr 27; 23(4):1436-41. PubMed ID: 18029372
    [Abstract] [Full Text] [Related]

  • 15. Dyslipidemia during sirolimus therapy in patients after liver transplantation.
    Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg Kh.
    Clin Transplant; 2004 Dec 27; 18(6):642-6. PubMed ID: 15516237
    [Abstract] [Full Text] [Related]

  • 16. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F, Di Sandro S, De Ruvo N, Spaggiari M, Montalti R, Ballarin R, Cappelli G, Gerunda GE.
    J Clin Gastroenterol; 2009 Mar 27; 43(3):280-6. PubMed ID: 19057397
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec 27; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 20. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007 Dec 27; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.